Resmetirom treatment resulted in a greater reduction in steatosis in the PNPLA3 CC wild-type LAMPS compared to the GG variant LAMPS, demonstrating genotype-specific inhibition of MASLD progression. The gene discussed is PNPLA3; the disease is steatosis.